Unanticipated risk in clinical research

Principles and Practice of Clinical Research

Volumn , Issue , 2007, Pages 77-95

  Straus, Stephen E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882506406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369440-9/50010-4     Document Type: Chapter

References (62)

1. Raper SE, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002, 13:163-175.
2. Raper SE, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylased deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80:148-158.
3. Savulescu J Harm, ethics committees and the gene therapy death. J Med Ethics 2001, 27:148-150.
4. Citizens for Responsible Care and Research website, www.circare.org/foia3/ihgtdocs.htm.
5. Hacein-Bey-Abina S, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
6. Federal Regulations for the Protection of Human Subjects. Title 45, Code of Federal Regulations, Part 46. Washington, DC, Office of the Federal Register, N Archives and Records Administration. Available at www.fda.gov.
7. Lopez C, Watamabe KA, Fox JJ 2'-Fluoro-5-iodo-aracytosine, a potent and selective anti-herpes virus agent. Antimicrob Agents Chemother 1980, 7:803.
8. Young CW, et al. Phase 1 evaluation of 2'-fluoro-5-iodo-l-p-darabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection. Cancer Res 1983, 43:5006.
9. Leyland-Jones B, et al. 2'-Fluoro-5-iodo-arabinosylcytosine, a new potent antiviral agent: Efficacy in immunosuppressed individuals with herpes zoster. J Infect Dis 1986, 154:430.
10. Whitley RJ, Gnann JW Acyclovir: A decade later. N Engl J Med 1993, 308:1448-1453.
11. Holland GN, Gottlieb MS, Yee RD, Schanker HM, Pettit TH Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol 1982, 93:393-402.
12. Crumpacker CS Ganciclovir. N Engl J Med 1996, 335:721-729.
13. Hantz O, Allaudeen HS, Ooka T, deClerq E, Trepo C Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, l-(2'deoxy-2'-fluoro-b-darabinofuranosyl) -5-iodocytosine (2-bromovinyl) -2'-deoxynridine. Antivir Res 1984, 4:187.
14. Fourel I, et al. Inhibitory effects of 2'-fluorinated arabinosylpyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 1990, 4:473-475.
15. Dusheiko G, Hoofnagle JH, Hepatitis B Oxford Textbook of Clinical Hepatology 1991, Oxford University Press, New York. N. McIntyre, J.P. Benhamou, J. Bircher, M. Rizzetto, J. Rodes (Eds.).
16. Hoofnagle JH, et al. Randomized controlled trial of recombinant human interferon-a in patients with chronic hepatitis B. Gastroenterology 1988, 95:1318-1325.
17. Perillo RP, et al. A randomized, controlled trial of interferon-a2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990, 323:295-301.
18. Paar DP, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HTV-infected subjects (ACTG 122b). Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992, American Society for Microbiology, Washington, DC.
19. Fried MW, et al. FIAU, a new oral antiviral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 1992, 16:127A.
20. Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Division of Health Sciences Policy, Institute of Medicine Review of the Fialuridine (FIAU) Clinical Trials 1995, National Academy Press, Washington, DC. F.J. Manning, M. Swartz (Eds.).
21. McKenzie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU) , an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 33:1099-1105.
22. Grem JL, King SA, Sorensen JM, Christian MC Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs 1991, 9:281-290.
23. Seiter K, et al. Undine allows dose escalation of 5-fluorouracil when given with N-phosphoacetyl-l-aspartate, methotrexate, and leucovorin. Cancer 1993, 71:1875-1881.
24. Sussman NL, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992, 16:60-65.
25. Stevenson W, et al. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proc 1995, 27:1219-1221.
26. Cui L, Yoon S, Schinazi RF, Sommadossi J-P Cellular and molecular events leading to mitochondrial toxicity of l-(2-deoxy-2-fluoro-l-p-d-arabinofuranosyl) -5-iodouracil in human liver cells. J Clin Invest 1995, 95:555-563.
27. Klecker RW, Katki AG, Collins JM Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-b-d-arabinofuranosyl) -5-iodouracil in U-937 and. Mol Pharmacol 1994, 46:1204-1209.
28. Richardson FC, Engelhardt JA, Bowsher RR Failuridine accumulates in DNA of dogs, monkeys, and rats following longterm oral administration. Proc Natl Acad Sci USA 1994, 91:12003-12007.
29. Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW Mammalian DNA polymerases a, p, and ft incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 1994, 33. 14620-1464.
30. Tennant BC, Gerin JL The woodchuck model of hepatitis B virus infection. The Liver: Biology and Pathobiology 1994, Raven Press, New York. 3rd ed. I.M. Arias (Ed.).
31. Tennant BC, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998, 28:179-191.
32. Chen CH, Vazquez-Padua M, Cheng Y-C Effect of anti-human immunodeficiency virus nucleotide analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991, 9:625-628.
33. Lewis LD, Hamzeh FM, Lietman PS Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in presence of 2',3'-dideoxycytidine. Antimicrob Agents Chemother 1992, 36:2061-2065.
34. Lewis W, Gonzalez B, Chomyn A, Papoian T Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 1992, 89:1354-1360.
35. Arnaudo E, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991, 337:508-510.
36. Freiman JP, Helfert KE, Hamrell MR, Stein DS Hepatomegaly with severe steatosis in HTV-seropositive patients. AIDS 1993, 7:379-385.
37. Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: Biochemical studies. J Am Soc Nephrol 1992, 3:1212-1219.
38. Lai KK, Gang DL, Zawacki JK Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddl). Ann Intern Med 1991, 115:283-284.
39. Bissuel F, et al. Fulminant hepatitis with severe lactate acidosis in HTV-infected patients on didanosine therapy. J Intern Med 1994, 235:367-371.
40. Maxson CJ, Greenfield SM, Tuner JL Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992, 87:708-713.
41. Broad W, Wade N Betrayers of the Truth 1982, Simon & Schuster, New York.
42. Kuhn TS The Structure of Scientific Revolutions 1996, Chicago, University of Chicago Press. 3rd ed.
43. Kevles DJ The Baltimore Case: A Trial of Politics, Science and Character 1998, Norton, New York.
44. Liaw Y-F, et al. Clinical and histological events preceding hepatitis B antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983, 84:216-219.
45. Weller FVD, et al. Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut 1985, 26:745-751.
46. Eli Lilly Company Lilly suspends trials of hepatitis B drug; "Adverse" events cited [Press release]. Wall Street Journal 1993, July 1.
47. Cimons M The deadly risks of research. Los Angeles Times 1993, August 25.
48. Altman LK Fatal drug trials raise question about "informed consent". New York Times 1993, October 5.
49. Hilts PJ After deaths, PDA is proposing suffer rules on drug experiments. New York Times 1993, A1. November 16.
50. Schwartz J And then the patients suddenly started dying: How NIH missed warning signs in drug test. Washington Post 1993, A1. September 7.
51. Hilts PJ PDA says 4 scientists broke rules in drug tests. New York Times 1994, A8. May 14.
52. Schwartz J Researchers cleared in drug trial deaths: NIH Advisory Panel's report on hepatitis studies at odds with finding by FDA. Washington Post 1994, June 3.
53. Hilts PJ Panel clears researchers in 5 deaths. New York Times 1995, 6. March 18.
54. Lai C-L, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 39:61-68.
55. Chan HL-Y, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferonalpha 2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240-250.
56. van Bömmel F, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421-1425.
57. Karayiannis P Hepatitis B virus: Old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003, 51:761-785.
58. Jacob JR, et al. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res 2004, 63:115-121.
59. Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Division of Health Sciences Policy, Institute of Medicine Review of the Fialuridine (FIAU) Clinical Trials 1995, National Academy Press, Washington, DC. F.J. Manning, M. Swartz (Eds.).
60. Code of Federal Regulations 21, Parts 300 to 499 1992, revised April 1, Office of the Federal Register, National Archives and Records Administration, Washington, DC.
61. Food Drug Administration Adverse experience reporting requirements for human drug and licensed biological products: 1995. Fed Reg 1994, 59:54046-54064. Proposed rules; 21 CFR, Part 20.
62. Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Division of Health Sciences Policy, Institute of Medicine Review of the Fialuridine (FIAU) Clinical Trials 1995, National Academy Press, Washington, DC. F.J. Manning, M. Swartz (Eds.).